Opexa Therapeutics (OPXA) 4.26 $OPXA
5 Best-Performing Biotech Stocks of June
Arpita Dutt - Zacks Investment Research - Tue Jul 05, 2:28PM CDT
These 5 biotech stocks managed to beat the downward trend and shot up more than 20% in the month of Jun 2016.
XBIT: 15.78 (+1.00), OPXA: 4.26 (+0.01), AVXL: 7.58 (+0.64), TTHI: 1.55 (-0.02), XNCR: 18.62 (+0.08)
5 Top Biotech Performers of 2016
Afrasiab Mian - Zacks Investment Research - Fri Jul 01, 4:19PM CDT
2016 has been a busy year for the Biotech industry. Let's take a look 5 of the strongest year-to-date (YTD) performers.
XBIT: 15.78 (+1.00), ARGS: 6.24 (+0.49), OPXA: 4.26 (+0.01), ANIP: 56.51 (-1.61), RPRX: 1.73 (+0.05)
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
Marketwire Canada - Thu May 12, 3:01PM CDT
Conference Call Scheduled Today at 4:30 PM ET
OPXA: 4.26 (+0.01)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results
Marketwire Canada - Tue May 10, 8:01AM CDT
THE WOODLANDS, TX--(Marketwired - May 10, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the quarter ended March 31, 2016 after the close of trading on Thursday, May 12th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. ET on Thursday, May 12th.
OPXA: 4.26 (+0.01)
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact
Marketwired - Wed Apr 27, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited to present at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, taking place April 28-30, 2016 in Vatican City.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Reports 2015 Year End Financial Results and Provides Corporate Update
Marketwired - Tue Mar 15, 3:01PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna(R) for multiple sclerosis (MS) and OPX-212 for neuromyelitis optica (NMO), today reported financial results for the year ended December 31, 2015, and provided an update on the Company's recent corporate developments.
OPXA: 4.26 (+0.01)
Opexa Launches Restructuring Initiative to Focus Use of Resources Ahead of Key Phase 2 Data Expected in Early Q4 2016
Marketwired - Wed Mar 02, 3:00PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it was implementing a restructuring initiative to focus the use of its resources, which should extend the Company's current cash runaway into the first quarter of 2017. The move comes as the Company prepares to complete its Phase IIb clinical trial in Secondary Progressive MS (SPMS) and report top-line data, with the announcement of such data currently expected in early Q4 2016.
OPXA: 4.26 (+0.01)
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference
Marketwired - Thu Jan 28, 8:01AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 11:00 a.m. EST in the Louis XVI Room. The conference will be held at the Waldorf Astoria Hotel in New York, NY.
OPXA: 4.26 (+0.01)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 11.30 (+0.35), GSK: 43.38 (+0.04), SYN: 1.89 (+0.04), OPXA: 4.26 (+0.01), FWP: 19.05 (+0.39), TEVA: 50.89 (+0.37), ABBV: 64.16 (+0.73), NVS: 82.13 (+0.33)
Global and Chinese Stem Cell Industry Report 2015-2018
M2 - Thu Dec 17, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9p2d5/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2015-2018" report to their offering. Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research. Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out. Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia. Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies. Global and China Stem Cell Industry Report, 2015-2018 highlights the followings: - Classification, application, industry chain definition, etc. of stem cells; - Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry; - Policies, upstream/midstream/downstream development, etc. of China stem cell industry; - Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises - Athersys - Beike Biotechnology - Caladrius Biosciences - Celgene - Cellular Biomedicine - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - Health & Biotech - LifeCell International - MEDIPOST - Mesoblast - Ocata - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - SALIAI - StemCells - Tian Qing Stem Cell - Tigenix - VCANBIO - Vitro Biopharma - ZhongKe Biopharm For more information visit http://www.researchandmarkets.com/research/f9p2d5/global_and
OPXA: 4.26 (+0.01), PSTI: 1.45 (+0.10), CYTX: 2.01 (+0.03), OSIR: 5.03 (+0.17), CLBS: 0.57 (+0.03), CELGZ: 1.43 (+0.08)
4 Stocks to Watch That are Trading Up Today on Heavy Volume
ACCESSWIRE - Tue Nov 24, 10:18AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that are trading up today on heavy volume in the market.
OPXA: 4.26 (+0.01), SUNE: 0.34 (unch), AEZS: 3.30 (-0.03)
Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch
BusinessWire - Tue Nov 17, 7:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has been selected one of the "Top Projects to Watch" by a panel of independent experts for the third consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 18-20, 2015 at the Hilton Boston Back Bay. Mr. Warma will present on Thursday, November 19 at 11:30 a.m. E.S.T.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO) Program
BusinessWire - Tue Nov 10, 3:05PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized otherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced results of a preclinical study, which show that T-cell immunotherapy with attenuated antigen-specific T-cells suppress the T-cell response to Aquaporin-4 (AQP4) in a dose-dependent manner, compared to vehicle control, as measured by reduction in both Aquaporin-4 reactive T-cell (ARTC) proliferation and associated cytokine activity. The results were statistically significant.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
BusinessWire - Tue Nov 10, 3:01PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial results for the three months ended September 30, 2015 and provided an update on the Company's recent corporate developments.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results
BusinessWire - Fri Nov 06, 7:30AM CST
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2015 after the close of trading on Tuesday, November 10th.
OPXA: 4.26 (+0.01)
Opexa Therapeutics to Host Analyst and Investor Event on November 10 in New York
BusinessWire - Mon Oct 19, 7:11AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Tuesday, November 10, 2015.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
BusinessWire - Thu Oct 15, 7:00AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement.
OPXA: 4.26 (+0.01)
5 Best-Performing Biotech Stocks of June
Arpita Dutt - Zacks Investment Research - Tue Jul 05, 2:28PM CDT
These 5 biotech stocks managed to beat the downward trend and shot up more than 20% in the month of Jun 2016.
XBIT: 15.78 (+1.00), OPXA: 4.26 (+0.01), AVXL: 7.58 (+0.64), TTHI: 1.55 (-0.02), XNCR: 18.62 (+0.08)
5 Top Biotech Performers of 2016
Afrasiab Mian - Zacks Investment Research - Fri Jul 01, 4:19PM CDT
2016 has been a busy year for the Biotech industry. Let's take a look 5 of the strongest year-to-date (YTD) performers.
XBIT: 15.78 (+1.00), ARGS: 6.24 (+0.49), OPXA: 4.26 (+0.01), ANIP: 56.51 (-1.61), RPRX: 1.73 (+0.05)
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
Marketwire Canada - Thu May 12, 3:01PM CDT
Conference Call Scheduled Today at 4:30 PM ET
OPXA: 4.26 (+0.01)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results
Marketwire Canada - Tue May 10, 8:01AM CDT
THE WOODLANDS, TX--(Marketwired - May 10, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the quarter ended March 31, 2016 after the close of trading on Thursday, May 12th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. ET on Thursday, May 12th.
OPXA: 4.26 (+0.01)
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact
Marketwired - Wed Apr 27, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited to present at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, taking place April 28-30, 2016 in Vatican City.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Reports 2015 Year End Financial Results and Provides Corporate Update
Marketwired - Tue Mar 15, 3:01PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna(R) for multiple sclerosis (MS) and OPX-212 for neuromyelitis optica (NMO), today reported financial results for the year ended December 31, 2015, and provided an update on the Company's recent corporate developments.
OPXA: 4.26 (+0.01)
Opexa Launches Restructuring Initiative to Focus Use of Resources Ahead of Key Phase 2 Data Expected in Early Q4 2016
Marketwired - Wed Mar 02, 3:00PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it was implementing a restructuring initiative to focus the use of its resources, which should extend the Company's current cash runaway into the first quarter of 2017. The move comes as the Company prepares to complete its Phase IIb clinical trial in Secondary Progressive MS (SPMS) and report top-line data, with the announcement of such data currently expected in early Q4 2016.
OPXA: 4.26 (+0.01)
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference
Marketwired - Thu Jan 28, 8:01AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, President and Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 11:00 a.m. EST in the Louis XVI Room. The conference will be held at the Waldorf Astoria Hotel in New York, NY.
OPXA: 4.26 (+0.01)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 11.30 (+0.35), GSK: 43.38 (+0.04), SYN: 1.89 (+0.04), OPXA: 4.26 (+0.01), FWP: 19.05 (+0.39), TEVA: 50.89 (+0.37), ABBV: 64.16 (+0.73), NVS: 82.13 (+0.33)
Global and Chinese Stem Cell Industry Report 2015-2018
M2 - Thu Dec 17, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9p2d5/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2015-2018" report to their offering. Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hundreds of diseases in clinical studies, of which about 50% is applied to blood diseases. In addition to blood diseases, tumors, neurological system diseases, heart disease, immune system diseases and the like are also important fields of stem cell clinical research. Up to now, only 12 sorts of stem cell products have been approved for marketing after rigorous safety and effectiveness review worldwide. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. allowance funds) and the capital support of key partners, very few companies have dropped out. Considerable stem cell therapy products are in clinical trials worldwide. For example, the United States National Institutes of Health (NIH) had registered 4,293 cord blood-related clinical research projects as of December 23, 2014 and 5,190 ones as of November 17, 2015, including 484 ones in East Asia. Restricted by policies, capital, technology and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese authorities have not accepted or reviewed any stem cell therapy of any medical institution except hematopoietic stem cells suitable for treating blood diseases; besides, the stem cell clinical applications of some hospitals pertain to the scope of pilot clinical studies. Global and China Stem Cell Industry Report, 2015-2018 highlights the followings: - Classification, application, industry chain definition, etc. of stem cells; - Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry; - Policies, upstream/midstream/downstream development, etc. of China stem cell industry; - Operation, stem cell business, etc. of 8 upstream companies and 20 midstream/downstream companies worldwide. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises - Athersys - Beike Biotechnology - Caladrius Biosciences - Celgene - Cellular Biomedicine - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - Health & Biotech - LifeCell International - MEDIPOST - Mesoblast - Ocata - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - SALIAI - StemCells - Tian Qing Stem Cell - Tigenix - VCANBIO - Vitro Biopharma - ZhongKe Biopharm For more information visit http://www.researchandmarkets.com/research/f9p2d5/global_and
OPXA: 4.26 (+0.01), PSTI: 1.45 (+0.10), CYTX: 2.01 (+0.03), OSIR: 5.03 (+0.17), CLBS: 0.57 (+0.03), CELGZ: 1.43 (+0.08)
4 Stocks to Watch That are Trading Up Today on Heavy Volume
ACCESSWIRE - Tue Nov 24, 10:18AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that are trading up today on heavy volume in the market.
OPXA: 4.26 (+0.01), SUNE: 0.34 (unch), AEZS: 3.30 (-0.03)
Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch
BusinessWire - Tue Nov 17, 7:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has been selected one of the "Top Projects to Watch" by a panel of independent experts for the third consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 18-20, 2015 at the Hilton Boston Back Bay. Mr. Warma will present on Thursday, November 19 at 11:30 a.m. E.S.T.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO) Program
BusinessWire - Tue Nov 10, 3:05PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized otherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced results of a preclinical study, which show that T-cell immunotherapy with attenuated antigen-specific T-cells suppress the T-cell response to Aquaporin-4 (AQP4) in a dose-dependent manner, compared to vehicle control, as measured by reduction in both Aquaporin-4 reactive T-cell (ARTC) proliferation and associated cytokine activity. The results were statistically significant.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
BusinessWire - Tue Nov 10, 3:01PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial results for the three months ended September 30, 2015 and provided an update on the Company's recent corporate developments.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results
BusinessWire - Fri Nov 06, 7:30AM CST
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2015 after the close of trading on Tuesday, November 10th.
OPXA: 4.26 (+0.01)
Opexa Therapeutics to Host Analyst and Investor Event on November 10 in New York
BusinessWire - Mon Oct 19, 7:11AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Tuesday, November 10, 2015.
OPXA: 4.26 (+0.01)
Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
BusinessWire - Thu Oct 15, 7:00AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement.
OPXA: 4.26 (+0.01)
